Category Archives: Stell Cell Research


Fighting cancer with every step to Patagonia – Essex News Daily

Photo Courtesy of Michael MankowichAbove, Michael Mankowich and his wife, Kathleen, in Patagonia

NUTLEY, NJ When Nutley resident Michael Mankowichs lower back started to bother him, he figured it was a souvenir from his earlier athletic days. Mike, 58, had been a top-notch wrestler at 132 pounds at Long Islands Commack North High School. Hed been an all-American, in fact, as well as a two-time all-Ivy, three-time New York state champ and three-time EIWA tournament placer as a wrestler at Cornell University. An old wrestlers injury was all it was, he figured, a physical reminder of a quick takedown of an opponent 40 years long forgotten.

But the pain did not go away.

Mike began to see a doctor and a chiropractor, and eventually he got an MRI. The news he received at Memorial Sloan Kettering Cancer Center in February 2017 was not good. He was diagnosed with multiple myeloma, a cancer that attacks the blood plasma cells responsible for creating disease-fighting antibodies.

They figured it out quickly at Sloan, he said recently, seated with his wife, Kathleen, in their Rutgers Place home. I kept it from Kathleen.

With this news, he became withdrawn, and his wife realized something was wrong. Mike told her what he had learned, and, as so often happens when a couple puts their heads together, they found some reason for hope: multiple myeloma is a blood disease in the bone marrow and, as such, does not metastasize.

Thats where all the action takes place, in the bone marrow, Mike said. You have to keep your chin up.

For treatment, he became part of a six-month chemotherapy clinical study. Mike was glad to be in the study, because most multiple myeloma patients go on chemotherapy for three months and then undergo a stem-cell transplant. He, however, would not.

A stem-cell transplant blows out the immune system, he said.

Kathleen, an administrative coordinator at Felician University School of Nursing, said her husband, a real estate management employee, did not break stride and never missed the commute to New York City during the clinical study.

A member of Nutley High Schools Class of 1976, Kathleen got on the computer.

When your spouse is diagnosed with an incurable cancer, you do a bit of research, she said.

She discovered the Multiple Myeloma Research Foundation website and learned it was founded 30 years earlier by a woman named Kathy Giusti, who was living with the disease.

That gave me hope, Kathleen said.

She also learned about a collaboration between MMRF and CURE Media Group called Moving Mountains for Multiple Myeloma, or MM4MM.

This collaboration promotes endurance events, undertaken by multiple myeloma patients, to places like Mount Fuji, Mount Kilimanjaro and Iceland. The treks raise money for research, as well as public awareness about the disease. A patient selected to participate in one of these exotic treks had to raise funds, but the trip itself was underwritten by Celgene, a pharmaceutical company headquartered in Summit.

Mike was interested and applied in November 2018 for a spot on a team going to Patagonia. He was interviewed and accepted on condition of raising $10,000 for MMRF research. He suggested that Kathleen accompany him, and they eventually raised $30,000 through social media and by asking friends, family and neighbors.

The online MMRF page devoted to Mikes fundraising shows a photograph of him with his arms around Kathleen and their daughter, Mary, a Class of 2020 NHS student.

In a letter featured on the page, Mike informs the reader that MMRF is one of the worlds leading private funders of myeloma research, with 10 new treatments approved by the Food and Drug Administration.

In August 2019, Mike and Kathleen were flown to Oregon to meet their teammates and to get a taste of what was in store for them in Patagonia. According to the MM4MM website: Each team is carefully selected, representing a microcosm of the myeloma community patients, caregivers, health care professionals and clinical trials managers, as well as representatives from our pharma partners, from CURE Magazine and the MMRF to emphasize the collaboration necessary to drive toward cures.

The foundation sent the group to Mount Hood, Mike said. It was the first time we met. What a great group of people. There were around 15 from all over the country, and there was one other couple, but no one else from New Jersey.

Four other multiple myeloma patients were in the group, he said. he team climbed for nine hours and then headed home.

To prepare for the trip to Patagonia, a region containing part of the Andes mountain range, Mike and Kathleen began a regime of long walks. For instance, theyd walk from Nutley to South Orange and went hiking in New Yorks Harriman State Park.

The MMRF website described the journey as one of arduous adventure: This team will traverse Patagonia crossing over glaciers, through deep valleys, and ascending challenging peaks. This is a powerful and life-changing experience, as the team overcomes challenges, pushes beyond perceived limits and honors loved ones and friends living with multiple myeloma.

For the trek, the team flew to El Calafate, Argentina. As the team embarked on different climbs, documentary filmmakers accompanied them.

The hiking was physically difficult, Mike said. We hiked in rain and incredible winds. In one particular hike, as soon as you felt the winds, you hit the ground. I was surprised nobody got hurt. Some of those slopes were pretty steep. But the scenery was unworldly, and there were condors.

Both Mike and Kathleen agreed that the most memorable sight was La Condorera, which their itinerary described as a nearly vertical massif, offering a home to one of the greatest concentrations of endangered condors in the world. A massif is a group of mountains standing apart from other mountains.

It was a difficult hike, Kathleen said. Youre ready to pass out getting to the top. But its so worth it. The panorama is a view of glaciers and condors. It was spectacular.

Mike and Kathleen returned home on Nov. 16, but there were no goodbyes at the airport. The team had grown so incredibly close that everyone felt they would be seeing each other again, a feeling grounded in the knowledge that multiple myeloma can be challenged and hopefully, one day, defeated.

Our goal in all of this is that you can have multiple myeloma and still do incredible things, Kathleen said.

Its an incentive to other patients to get out there and enjoy their lives, Mike said. And find a cure for multiple myeloma. I have a little bias. I have it.

FEATURED, MOBILE

Go here to read the rest:
Fighting cancer with every step to Patagonia - Essex News Daily

New Gene Therapy Successfully Sends Six Patients With Rare Blood Disorder Into Remission – IFLScience

Six patients with a rare blood disease are now in remission thanks to a new gene therapy. The condition, known as X-CGD, weakens the immune system leaving the body vulnerable to a range of nasty infections and shortens a persons lifespan. It is normally treated using bone marrow transplants, but matching donors to patients can be tricky and time-consuming and the procedure comes with risks.

A team led by UCLA recently treated nine people with the disease and six successfully went into remission, allowing them to stop other treatments. All six patients are doing well and havent suffered any adverse effects.

X-CGD is a form of chronic granulomatous disease (CGD). People with CGD have an inherited mutation in one of five genes involved in helping their immune system attack invading microbes with a burst of chemicals. This means that CGD sufferers have weaker immune systems than healthy people, so they have a greater risk of getting infections. These infections can be life-threatening, particularly if they affect the bones or cause abscesses in vital organs.

X-CGD is the most common type of CGD and only affects males. It is caused by a mutation in a gene on the X-chromosome. Current treatments are limited to targeting the actual infections with antibiotics as well as bone marrow transplants. Bone marrow contains stem cells that develop into white blood cells, so bone barrow from a healthy donor can provide a CGD patient with healthy white blood cells that can help their body to fend off disease.

However, bone marrow transplants are far from ideal. The patient has to be matched to a specific donor, and the body can reject the implanted bone marrow. That means that following a transplant, the patient needs to take anti-rejection drugs for at least six months.

For their new treatment, researchers removed blood cell-forming stem cells from the patients themselves and genetically modified them so that they no longer carried the unwanted mutation. Then, the edited stem cells were returned to their bodies, ready to produce healthy new infection-fighting white blood cells.

This is the first time this treatment has been used to try to correct X-CGD. The researchers followed up with the nine patients but sadly, two passed away within three months of the treatment. Its important to note that their deaths were not a result of the treatment but of rather severe infections that they had been suffering from for a long time. The remaining seven were followed for 12 to 36 months all remain free from infections related to their condition, and six have been able to stop taking preventative antibiotics entirely. The results are reported in Nature Medicine.

None of the patients had complications that you might normally see from donor cells and the results were as good as youd get from a donor transplant or better, said Dr Donald Kohn, a member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLAand a senior author of the paper.

Whats more, four new patients have also been treated since the initial research was conducted. None experienced any adverse reactions and all remain infection-free. Now, the team plans to conduct a bigger clinical trial to further test the safety and efficacy of their new treatment, with the hopes that it may one day become available to the masses.

Read more:
New Gene Therapy Successfully Sends Six Patients With Rare Blood Disorder Into Remission - IFLScience

The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017 – Yahoo Finance

The market is estimated to grow with a CAGR of 22. 8% from 2018-2025. The growth of the market is driven by the factors such as rising chronic disease due to change in lifestyle and growing interest in human microbiome treatment approach.

New York, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Human Microbiome Market to 2025 - Regional Analysis and Forecasts by Product, Disease, Application, and Country" - https://www.reportlinker.com/p05764187/?utm_source=GNW Whereas, stringent regulatory environment and lack of awareness about human microbiome science is likely to have a negative impact on the growth of the market in the coming years.

Probiotics, prebiotics dietary supplements and foods that contain live microbes have been studied thoroughly to assess their effects on human health.The Gut Health Congress was held in Hong Kong Asia in 2018, the conference explore in detail of diet & personalised nutrition, gastrointestinal microbiome and several case studies with regards to clinical studies, diagnostics studies, treatment methods, biomarker developments, molecular therapy and gastrointestinal diseases.

Also, the 5th Microbiome R&D and Business Collaboration Congress was held in Taiwan, Asia in March 2019, the conference focused on recent developments in gut microbiome, skin microbiome, infant, women and oral health, therapeutics, microbiome and diet.Also, many companies are designing and developing many microbiome therapies. Thus, the increasing focus on human microbiome therapies is the prime factor driving the growth of human microbiome market in the coming years.

Japan is anticipated to lead the adoptions of Human microbiome across the Asia Pacific region through the forecast period.Researchers from Japan are using the outcomes of studies on centenarians in the country to try and produce new products that will replicate the beneficial aspects of their microbiota.

The goal of the collaboration is to solve few of the major technological hurdles in advancing stem cell research. Moreover, Cykinso (Tokyo) received the US$ 2.3 million (270 million yen) funds from the Regional Health Care Industry Support Fund, develop and sell Mykinso or a test kit for intestinal flora. The company plans to use the funds for business development purposes, which include using the data collected from the intestinal flora tests to develop a system for offering nutritional guidance. Thus, the investments and the initiatives taken by the government are likely to propel the growth of the market in the forecast period.

Exhibit: Rest Of Asia Pacific Human microbiome Market Revenue and Forecasts to 2027 (US$ Bn)

ASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy ProductProbioticsFoodsPrebioticsMedical FoodsDiagnostic DeviceDrugsSupplementsASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy DiseaseObesityDiabetesAutoimmune DisordersCancerMental DisordersOthersASIA PACIFIC HUMAN MICROBIOME- MARKET SEGMENTATIONBy ApplicationTherapeuticsDiagnostics

By CountryU.S.CanadaMexico

Companies MentionedEnteromeMicroBiome Therapeutics, LLCRebiotix Inc.Yakult Honsha Co., Ltd.Osel Inc.Vedanta Biosciences, Inc.Metabiomics CorporateSynthetic Biologics, Inc.DuPontBiomX Ltd.

Reasons to BuySave and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human microbiome market.Highlights key business priorities in order to assist companies to realign their business strategies.The key findings and recommendations highlight crucial progressive industry trends in the global human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.Read the full report: https://www.reportlinker.com/p05764187/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post here:
The Asia Pacific human microbiome market is expected to reach US$ 207.81 Mn in 2025 from US$ 41.73 in 2017 - Yahoo Finance

The 5 Best Traits Of Micropreneurs, The Smallest Of Small Business Owners – Forbes

Even though I've taken a full-time role writing content for a fintech company, I'm still running my content agency part-time. I will always be an entrepreneur at heartnay, a micropreneur, which I've written about many times.

A micropreneur (or microbusiness) is one that operates on a very small scale, with no more than five employees. We micropreneurs are a breed all our own, and there's plenty to admire about us. So let's pat ourselves on the back, shall we?

Whether youre a micropreneur yourself or thinking about hiring or partnering with one, here are the ... [+] key traits that make us so successful as entrepreneurs.

Whether youare a micropreneur yourself or are thinking about hiring or partnering with one, here are some of our best traits:

When there's no one around to help you solve a problem, what do you do? Solve it, of course. Micropreneurs rely on themselves togit-'er-done, and that makes us strong. It's funnynow that I'm working with an extraordinary team of people in my new job, I realize how long I've been problem-solving on my own. I've gotta say, it's kind of amazing to find people whom I can also trust to help find a solution as good as (or better than) what I would have come up with on my own. And the fact that I've been doing that solo for so many years makes me a great asset to the team.

The drawback to this trait:I guess in my personal life, this isn't always an asset. Sometimes my friends just want to vent about a problem they're having, and I'm already on top of trying to solve it!

Once a micropreneur, always a micropreneur. I don't know one person who has owned a business, shut it down, and never started something new. I myself can count at least five businesses I've started (going back to college when I launched Snazzy Baskets, a custom gift basket brand that didn't make it long). I know in my heart I will start more businesses in the future; it's exciting to wonder what they'll be centered on.

It's like our brains are wired to find opportunities. Saying we're opportunistic isn't accurate; it's more that we find gaps in existing solutions or come up with new and better ways to do things. And that is what makes for the innovation that the world turns on.

The drawback to this trait:We are never, ever satisfied. There's always a better way, and looking for it can be exhausting (see #1).

Other Articles FromAllBusiness.com:

Ask 100 micropreneurs how they manage their daily tasks, and you'll get 100 answers. Maybe 102. That's because we don't prescribe to how others do things; we need to forge our own paths. For me, my day consists of constantly being pinged by Google Calendar tasks, as well as Alexa shouting reminders to me from the kitchen. Sometimes, just for fun, I'll write things on paper.

I love that we micropreneur types are unique and that we don't take the path most traveled for anything we do. I love hearing how other business owners manage things and sometimes modify their solutions.

The drawback to this trait: Ever heard the phrase "Don't reinvent the wheel"? Well ... we can't help doing exactly that, over and over.

Being a micropreneur doesn't mean we are always isolated (though, yes, it sometimes does). We don't need guidance, which makes us uber-productive in our home offices away from other humans. But when we are part of a team, we also thrive. We're like the kid in your school group project who essentially carried the slackers. Because we have such high expectations for our own work, we apply the same diligence when we're working with others.

The drawback to this trait: It's probably hard to have such a go-getter on a team for those who don't operate the same way. It can be easy for us to dominate a project. It's the Type A in us coming out.

So, on a personal note, I'm single. I have engaged in more dating app conversations than I care to count, and despite advice telling me not to ask this (apparently, it's a very clich thing to do), I actually like asking what people do for a living. Because I'm genuinely curious.

Ooh, you're an engineer in the aerospace industry? What sort of technologies are we launching into space?

A doctor involved in stem cell research? Tell me more!

I like understanding what people do and what attracted them to that role. I'm the same with my marketing clients: I want to know what makes their businesses tick so I can make it shine through words.

The drawback to this trait: Again, I think a saying communicates it all: "Curiosity killed the cat." When we spend so much time being curious or going down a research rabbit hole (I know about those), we are less productive.

Micropreneurs are entrepreneurs, certainly, but they're also creatures of their own design. If you are a micropreneur, what other qualities do you love about yourself?

RELATED:Take the 4-Week Micropreneur Challenge to Bring Your Small Business to the Next Level

This article was originally published on AllBusiness. See all articles by Susan Guillory.

More here:
The 5 Best Traits Of Micropreneurs, The Smallest Of Small Business Owners - Forbes

Stem Cell Banking Outsourcing Market Competitive Research And Precise Outlook 2019 To 2025 – NY Telecast 99

The Stem Cell Banking Outsourcing Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2019-2025. The Stem Cell Banking Outsourcing market report is a valuable source of data for business strategists. It provides the industry overview with market growth analysis with a historical & futuristic perspective for the following parameters; cost, revenue, demands, and supply data (as applicable). The report explores the current outlook in global and key regions from the perspective of players, countries, product types and end industries. This Stem Cell Banking Outsourcing Market study provides comprehensive data that enhances the understanding, scope, and application of this report.

Top Companies in the Global Stem Cell Banking Outsourcing MarketCCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell.

Stem Cell Banking refers to the human stem cell transplantation for the purpose, with acquisition, processing, preservation and provides the ability to differentiate stem cell storage bank, has been called the life bank.

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025/inquiry?Mode=46&Source=NY

The Stem Cell Banking Outsourcing market can be divided based on product types and its sub-type, major applications and Third Party usage area, and important regions.

This report segments the global Stem Cell Banking Outsourcing Market on the basis ofTypesare:Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

On The basis Of Application, the Global Stem Cell Banking Outsourcing Market is Segmented into:Diseases Therapy, Healthcare

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025/discount?Mode=46&Source=NY

Regions are covered by Stem Cell Banking Outsourcing Market Report 2019 To 2025.

North America, Europe, China, Japan, Southeast Asia, India.North America (USA, Canada and Mexico).Europe (Germany, France, UK, Russia and Italy).Asia-Pacific (China, Japan, Korea, India and Southeast Asia).

Significant Features that are under Offering and Key Highlights of the Reports:

-Detailed overview of Stem Cell Banking Outsourcing Market-Changing Stem Cell Banking Outsourcing market dynamics of the industry-In-depth market segmentation by Type, Application etc.-Historical, current and projected Stem Cell Banking Outsourcing market size in terms of volume and valueRecent industry trends and developments-Competitive landscape of Stem Cell Banking Outsourcing Market-Strategies of key players and product offerings-Potential and niche segments/regions exhibiting promising growth.

https://www.marketinsightsreports.com/reports/01231062511/global-stem-cell-banking-outsourcing-market-size-status-and-forecast-2019-2025?Mode=46&Source=NY

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.Free Competitive analysis of any 5 key market players.Free 40 analyst hours to cover any other data point.

In this study, the years considered to estimate the market size of Stem Cell Banking Outsourcing are as follows:

History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025

Market Insights Reports is an online market research reports library of 500,000 in-depth studies of over 5000 micro markets. Market Insights Reports offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Irfan Tamboli Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Follow this link:
Stem Cell Banking Outsourcing Market Competitive Research And Precise Outlook 2019 To 2025 - NY Telecast 99

Global Stem Cell Reconstructive Market 2019 Revenue, Opportunity, Forecast and Value Chain 2024 – Science of Change

TheGlobalStem Cell ReconstructiveMarket Growth 2019-2024begins with a market overview and covers market research data that is relevant for new market entrants or established players. The report comprehensively prepared with main focus on the segmentation, competitive landscape, geographical growth, market forecast (2019 to 2024) and major market dynamics including drivers, restraints, and opportunities. The report throws light on key production, revenue, and consumption trends. Key strategies of the companies operating in the market along with a detailed analysis of the competition and leading companies of the globalStem Cell Reconstructivemarket has been highlighted in this report. Additionally, a business overview, revenue share, and SWOT analysis of the leading players in the market have been provided in the report.

For each manufacturer covered, this report analyzes its manufacturing sites, capacity, production, ex-factory price, revenue, and market share in the global market. The followingManufacturersare covered:Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad, Medi-post, Anterogen, Molmed

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html#sample

Market Bifurcation:

The report splits the globalStem Cell Reconstructivemarket on the basis of product and segmentation. The study includes significant sectors and categories of the market. Both rapidly and slowly rising segments of the market are analyzed. The market share and the size of each division and sub-division are covered in this report. The current and upcoming opportunities in the market are included in this research study.

From a global perspective, this report represents the overall market size by analyzing historical data and future prospects. Regionally, this report categorizes the production, apparent consumption, export and import in

Some Notable Report Offerings

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-stem-cell-reconstructive-market-growth-status-and-382312.html

Moreover, the globalStem Cell Reconstructivemarket analyzes the development patterns of the business through authentic investigation and evaluations of future prospects dependent on complete research. The market measure regarding volume with last years growth amount and revenue is planned for the review time span (2019-2024). This report quickly delivers the market patterns, size, development, and estimation for the period 2019-2024. This analysis report also assists rivals as per particular areas for development and compound growth rate.

Contact Us

Mark StoneSales ManagerPhone:+1-201-465-4211Email:[emailprotected]Web:www.fiormarkets.com

See more here:
Global Stem Cell Reconstructive Market 2019 Revenue, Opportunity, Forecast and Value Chain 2024 - Science of Change

Development of guidelines for research on stem-cell based embryo models – BioNews

27 January 2020

New international guidelines are being developed to establish ethical parameters for scientists working with human stem cell based embryo models.

Also known as SHEEFS (synthetic human entities with embryo-like features) these embryo models are not made from eggs and sperm but grown from pluripotent stem cells. They have great potential in allowing researchers to study early embryo development, and could reduce the number of animals and human embryos used in research. Knowledge gained from these models has the potential to improve understanding of pregnancy loss and congenital defects (see BioNews1015.

The International Society for Stem Cell Research (ISSCR) announced that they have organised a working group to develop detailed guidance, expected to be released in early 2021. In the meantime, they have collated a list of 'principles and current recommendations' that they encourage researchers and institutions to follow.

The project is being led by Professor Robin Lovell-Badge, of the Francis Crick Institute, London with a working group that also includes further representatives from the UK, USA, Canada, Japan, the Netherlands and China.

The announcement was accompanied by an article in Stem Cell Reports, which discusses how legal definitions of embryos across different jurisdictions can mean they may be regulated as embryos in some countries, and not in others.

The review is timely, as Nature reports that US researchers are finding it difficult to get funding for studies using SHEEFs. A 1996 federal law bans any state funding of research that creates or destroys human embryos, and it appears that uncertainty around whether this applies to stem-cell models is leading to funders such as the National Institutes of Health (NIH) to err on the side of caution.

'The NIH of course is struggling with the question when is an embryo not an embryo,' co-author of the Stem Cell Reports paper, Dr Janet Rossant, a developmental biologist at the Hospital for Sick Children, Toronto, Canada told Nature. 'I would also absolutely say we're not close to a line that should not be crossed.'

Originally posted here:
Development of guidelines for research on stem-cell based embryo models - BioNews

Informatics Approaches for Harmonized Intelligent Integration of Stem | SCCAA – Dove Medical Press

Joseph Finkelstein,1 Irena Parvanova,1 Frederick Zhang2

1Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Center for Bioinformatics and Data Analytics, Columbia University, New York, NY, USA

Correspondence: Joseph FinkelsteinDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, Icahn L2-36, New York, NY 10029, USATel +1 212-659-9596Email Joseph.Finkelstein@mssm.edu

Abstract: As biomedical data integration and analytics play an increasing role in the field of stem cell research, it becomes important to develop ways to standardize, aggregate, and share data among researchers. For this reason, many databases have been developed in recent years in an attempt to systematically warehouse data from different stem cell projects and experiments at the same time. However, these databases vary widely in their implementation and structure. The aim of this scoping review is to characterize the main features of available stem cell databases in order to identify specifications useful for implementation in future stem cell databases. We conducted a scoping review of peer-reviewed literature and online resources to identify and review available stem cell databases. To identify the relevant databases, we performed a PubMed search using relevant MeSH terms followed by a web search for databases which may not have an associated journal article. In total, we identified 16 databases to include in this review. The data elements reported in these databases represented a broad spectrum of parameters from basic socio-demographic variables to various cells characteristics, cell surface markers expression, and clinical trial results. Three broad sets of functional features that provide utility for future stem cell research and facilitate bioinformatics workflows were identified. These features consisted of the following: common data elements, data visualization and analysis tools, and biomedical ontologies for data integration. Stem cell bioinformatics is a quickly evolving field that generates a growing number of heterogeneous data sets. Further progress in the stem cell research may be greatly facilitated by development of applications for intelligent stem cell data aggregation, sharing and collaboration process.

Keywords: stem cells, data integration, databases

This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/.The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Read the original post:
Informatics Approaches for Harmonized Intelligent Integration of Stem | SCCAA - Dove Medical Press

First pain treatment using human stem cells developed – THE WEEK

Scientists have developed the first treatment for pain using human stem cells, which provides lasting relief in mice in a single treatment, without side effects. If the treatment is successful in humans, it could be a major breakthrough in the development of new non-opioid, and non-addictive pain management, the researchers said.

"Nerve injury can lead to devastating neuropathic pain and for the majority of patients there are no effective therapies," said Greg Neely, an associate professor at the University of Sydney in Australia.

"This breakthrough means for some of these patients, we could make pain-killing transplants from their own cells, and the cells can then reverse the underlying cause of pain," Neely said in a statement.

The study, published in the journal Pain, used human induced pluripotent stem cells (iPSCs) derived from bone marrow to make pain-killing cells in the lab.

The iPSCs are cells which can develop into many different cell types in the body during early life, and growth.

The researchers then put the cells into the spinal cord of mice with serious neuropathic pain, caused by damage or disease affecting the nervous system.

"Remarkably, the stem-cell neurons promoted lasting pain relief without side effects," said study co-author Leslie Caron.

"It means transplant therapy could be an effective and long-lasting treatment for neuropathic pain. It is very exciting," Caron said.

Because the researchers can pick where to put the pain-killing neurons, they can target only the parts of the body that are in pain.

"This means our approach can have fewer side effects," said John Manion, a PhD student and lead author of research paper.

The stem cells used were derived from adult blood samples, the researchers noted.

Their next step will be to perform extensive safety tests in rodents and pigs.

They will then move to human patients suffering chronic pain within the next five years.

Go here to see the original:
First pain treatment using human stem cells developed - THE WEEK

Weekly pick of brain tumour research news from around the world – Brain Tumour Research

The first symposium of the South West Brain Tumour Centre was held on Thursday at Derriford Hospital in Plymouth. During a fascinating and very well attended event, topics covered included the mechanism of tumour development, new drug targets, new biomarkers and brain tumour imaging. The South West Brain Tumour centre is of course one of the UK Centres of Excellence funded by Brain Tumour Research.

A really big cancer wide story this week is here Immune discovery 'may treat all cancer' applicable to some solid tumours but not yet brain it really shows the direction of travel toward immunotherapy I have recommended this book before but if interested please do read The Breakthrough by Charles Graeber it is available on Amazon and you can read reviews here - http://www.charlesgraeber.com.Researchers uncover novel drug target for glioblastoma by revealing a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. This pathway shows that glioma stem cells ability to access key nutrients in their surrounding microenvironment is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma.

An intelligent molecule could significantly extend the lives of patients with glioblastoma, research finds. The molecule, called ZR2002, which can be administered orally and is capable of penetrating the blood-brain barrier, could delay the multiplication of glioblastoma stem cells resistant to standard treatment. According to scientists in the Metabolic Disorders and Complications Program at the Research Institute of the McGill University Health Centre (RI-MUHC) the ZR2002 molecule is designed to kill two birds with one stone: on top of attacking the tumour, it destroys its defence system.

Researchers find clues to drug resistance in medulloblastoma subtype.US scientists have identified specific types of cells that cause targeted treatment to fail in a subtype of medulloblastoma. They found while the majority of cells responded to treatment, diverse populations within the tumour continue to grow leadingto treatment resistance. They concluded that the diversity of cells within tumours allow them to become rapidly resistant to precisely targeted treatments," and that due to this tumour cell diversity, molecularly precise therapies should be used in combinations to be effective."

Nanoparticles deliver 'suicide gene' therapy to paediatric brain tumours growing in mice So-called "suicide genes" have been studied and used in cancer treatments for more than 25 years. Researchers report here that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a ''suicide gene'' to paediatric brain tumour cells implanted in the brains of mice.

According to a study that uncovers an unexpected connection between gliomas and neurodegenerative diseases a protein typically associated with neurodegenerative diseases like Alzheimers might help scientists explore how gliomas become so aggressive. The new study, in mouse models and human brain tumour tissues, was published in Science Translational Medicine and found a significant expression of the protein TAU in glioma cells, especially in those patients with better prognoses. Patients with glioma are given a better prognosis when their tumour expresses a mutation in a gene called isocitrate dehydrogenase 1 (IDH1). In this international collaborative study led by the Instituto de Salud Carlos III-UFIEC in Madrid, Spain, those IDHI mutations stimulated the expression of TAU. Then, the presence of TAU acted as a brake for the formation of new blood vessels, which are necessary for the aggressive behaviour of the tumours.

'Innovative research award' helps Colorado scientists block brain cancer escape routes Cancers used to be defined by where they grow in the body - lung cancer, skin cancer, brain cancer, etc. But work in recent decades has shown that cancers sharing specific genetic changes may have more in common than cancers that happen to grow in an area of the body. For example, lung cancers, skin cancers, and brain cancers may all be caused by mutation in a gene called BRAF. Drugs targeting BRAF have changed the treatment landscape for melanoma, an aggressive form of skin cancer, and are also in use against lung cancers and brain cancers with BRAF mutations. It is really worth clicking through to read more on this and the ultimate goal of identifying new potential targets for combination therapy and new agents that could be added to BRAF inhibiting drugs in brain cancer to keep the cancer from developing resistance.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Read more:
Weekly pick of brain tumour research news from around the world - Brain Tumour Research